Nature Communications (Oct 2023)

Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera

  • Geoffrey B. Hutchinson,
  • Olubukola M. Abiona,
  • Cynthia T. Ziwawo,
  • Anne P. Werner,
  • Daniel Ellis,
  • Yaroslav Tsybovsky,
  • Sarah R. Leist,
  • Charis Palandjian,
  • Ande West,
  • Ethan J. Fritch,
  • Nianshuang Wang,
  • Daniel Wrapp,
  • Seyhan Boyoglu-Barnum,
  • George Ueda,
  • David Baker,
  • Masaru Kanekiyo,
  • Jason S. McLellan,
  • Ralph S. Baric,
  • Neil P. King,
  • Barney S. Graham,
  • Kizzmekia S. Corbett-Helaire

DOI
https://doi.org/10.1038/s41467-023-41661-4
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Multivalent antigen display is a fast-growing area of interest toward broadly protective vaccines. Current nanoparticle-based vaccine candidates demonstrate the ability to confer antibody-mediated immunity against divergent strains of notably mutable viruses. In coronaviruses, this work is predominantly aimed at targeting conserved epitopes of the receptor binding domain. However, targeting conserved non-RBD epitopes could limit the potential for antigenic escape. To explore new potential targets, we engineered protein nanoparticles displaying coronavirus prefusion-stabilized spike (CoV_S-2P) trimers derived from MERS-CoV, SARS-CoV-1, SARS-CoV-2, hCoV-HKU1, and hCoV-OC43 and assessed their immunogenicity in female mice. Monotypic SARS-1 nanoparticles elicit cross-neutralizing antibodies against MERS-CoV and protect against MERS-CoV challenge. MERS and SARS nanoparticles elicit S1-focused antibodies, revealing a conserved site on the S N-terminal domain. Moreover, mosaic nanoparticles co-displaying distinct CoV_S-2P trimers elicit antibody responses to distant cross-group antigens and protect male and female mice against MERS-CoV challenge. Our findings will inform further efforts toward the development of pan-coronavirus vaccines.